Amplifier doses first patients in Phase 1b trial of ATX-304 and expands its Series A to $33.25M

Cambrian Bio/Pipeline companies

Amplifier Therapeutics dosed the first patient in an 8-week, randomized, placebo-controlled Phase 1b trial of ATX-304 in prediabetic, overweight or obese adults in the European Union, with focus on safety and pharmacokinetics and exploratory metabolic and muscle function endpoints. The company also closed an expansion of its Series A to $33.25M total.

• Phase 1b: 8-week, double-blind, randomized placebo-controlled study in EU; prediabetic, overweight or obese participants; safety and PK primary endpoints.
• ATX-304 is pan-AMPK and mitochondrial activator targeting cardiometabolic diseases; exploratory endpoints assess metabolic parameters and muscle function.
• Series A expanded to $33.25M total; new investors RA Capital Management and Future Ventures joined Cambrian Bio's lead investment.